Sera Prognostics Inc

NASDAQ SERA

Download Data

Sera Prognostics Inc Cash Flow Coverage Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 213.94%

Sera Prognostics Inc Cash Flow Coverage Ratio 1 year YoY Change (%) is 213.94% for the Trailing 12 Months (TTM) ending March 31, 2024, a 176.64% change year over year. The cash flow coverage ratio evaluates a company's ability to cover its interest expense with its operating cash flow after deducting capital expenditures. It is calculated by dividing the difference between operating cash flow and capital expenditures by interest expense. This ratio indicates the company's ability to generate enough cash flow to service its interest payments. A higher ratio signifies better coverage and financial stability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Sera Prognostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -417.57, a 77.34% change year over year.
  • Sera Prognostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -1,842.38, a -14,730.22% change year over year.
  • Sera Prognostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -12.42, a -17.43% change year over year.
  • Sera Prognostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -10.58.
NASDAQ: SERA

Sera Prognostics Inc

CEO Dr. Gregory C. Critchfield M.D., M.S.
IPO Date July 15, 2021
Location United States
Headquarters 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees 55
Sector Healthcare
Industry Diagnostics & research
Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Similar companies

FONR

Fonar Corporation

NA

NA

OLK

Olink Holding AB ADR

NA

NA

XGN

Exagen Inc

NA

NA

DRIO

DarioHealth Corp

NA

NA

PSNL

Personalis Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email